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uptake reported to date. As shown in Figure 1b , V-9302 inhibited ASCT2-mediated glutamine uptake in human cells in a concentrationdependent fashion and exhibited a 100-fold improvement in potency (V-9302 half-maximal inhibitory concentration (IC 50 ) = 9.6 µM) over γ-L-glutamyl-p-nitroanilide (GPNA; IC 50 = 1,000 µM) 14 , a previously reported inhibitor of glutamine uptake. Using a panel of 3 H-labeled amino acids that are transported by multiple transporter systems, including glutamine and other solutes not transported by ASCT2 (Supplementary Fig. 1 ), we observed that V-9302 preferentially inhibited glutamine transport at a concentration of up to tenfold greater than its IC 50 (Fig. 1c,d) . Similarly, V-9302 was found to be capable of inhibiting the uptake of another ASCT2 substrate, leucine (Fig. 1d,e) , suggesting that its amino acid transport inhibitory profile was specific for ASCT2 but not restricted to glutamine. To confirm that V-9302 binds ASCT2, we employed the drug affinity responsive target stability (DARTS) technique 15 using HEK-293 cells expressing a tetracycline-inducible ASCT2 vector. The DARTS technique is a target-identification strategy that capitalizes upon reduction in protease susceptibility of a target protein upon drug binding 15 . We observed protection of ASCT2 from proteolysis in a V-9302-concentration-dependent manner ( Fig. 1f and Supplementary  Fig. 2a ), indicating that there is a stable V-9302-ASCT2 interaction and therefore implying that ASCT2 is a putative V-9302 target. Interestingly, the ASCT2 paralog, ASCT1 (encoded by SLC1A4), was not stabilized in the presence of V-9302 ( Supplementary Fig. 2b ), suggesting that V-9302 exhibits ASCT2 selectivity.
In silico modeling
To model points of interaction between V-9302 and ASCT2, we used an in silico homology model of human ASCT2 (hASCT2) 16 . We found that V-9302 was compatible with the orthosteric amino acid-binding pocket of hASCT2, which is localized within the transmembrane region of the protein (Fig. 2a) . The conserved α-aminoacid headgroup of V-9302 appeared to form key interactions within the zwitterion recognition site (Fig. 2b) , which has been shown through crystallographic data to recognize amino acids and derivatives thereof 16 . Similarly, docking glutamine into ASCT2 resulted in direct overlap with the putative binding pocket occupied by V-9302 (Fig. 2c) . To validate the specific interactions observed, we performed an in silico alanine scan of residues located within the putative V-9302-binding pocket (Fig. 2d) . The overall docking scores for binding pockets harboring p.S353A or p.D464A suggest strong corresponding side chain interactions at these residues (Fig. 2d) . Consistent with results from the amino acid selectivity assay (Fig. 1c,d ), V-9302 interactions with L-type amino acid transporter 1 (LAT1), another transporter of glutamine, suffered steric hindrance penalties (Fig. 2e,f) . Interface scores for glutamine in ASCT2 and LAT1 were favorable in both models, whereas those for V-9302 were not (Fig. 2f) . These two neutral amino acid transporters are frequently coexpressed and exhibit overlapping substrate specificity, which has led some to propose cooperatively between ASCT2 and LAT1 in certain cancers 17, 18 .
In vitro evaluation of V-9302
To evaluate the effects of V-9302 on human cancer cells, we conducted an in vitro efficacy screen of 29 human cancer cell lines spanning three tumor types (Fig. 3a) . Given the anaplerotic nature of glutamine, we used an ATP-dependent assay of viability as a primary screen, which was validated in an independent follow-up screening.
In the primary screen, we observed that V-9302 exposure reduced in vitro viability by at least 20% in more than half of the cell lines screened, with sensitivity to V-9302 exposure not obviously linked to select mutational status (Supplementary Fig. 3 ). Follow-up screening was carried out in a subset of colorectal cancer (CRC) cell lines that exhibited variable sensitivities to V-9302 in the primary screen. Using three independent assays lacking ATP dependency, we confirmed that V-9302 exposure led to reduced cellular viability and increased cell death ( Supplementary Fig. 4 ) 19 . Although V-9302 impacted either viability or cell death to varying degrees across the panel of cell lines screened, certain particularly sensitive cell lines, including RKO, SW620, and LIM2537, exhibited dramatically decreased viability and increased cell death. To elucidate biological correlates of V-9302 sensitivity, we compared cell line sensitivity with ASCT2 levels (Supplementary Fig. 5 ) as well as viability in media depleted of ASCT2 substrates (Supplementary Fig. 6 ). Neither membraneassociated nor total ASCT2 levels correlated with V-9302-dependent changes in viability. However, cell lines sensitive to V-9302 exposure exhibited reduced viability and increased cell death when propagated in glutamine-or ASCT2-substrate-depleted media. Finally, we examined cellular viability after exposure to V-9302 or CB-839 in four human CRC cell lines (Fig. 3b) . The half-maximal effective concentration (EC 50 ) for the four CRC cell lines exposed to V-9302 ranged from approximately 9-15 µM, and CB-839 did not exhibit appreciable activity under identical conditions. Glutamine plays critical roles in T cell proliferation and activation 20 . We evaluated the effects of V-9302 on activated CD8 + T cells in vitro and found T cell viability unchanged relative to that following vehicle treatment (Supplementary Fig. 7a ). T cell activation was also not impaired after V-9302 exposure (Supplementary Fig. 7b ).
Determinants of response to V-9302
To elucidate determinants of the response to V-9302 in vitro, we carried out shRNA knockdown of ASCT2 in HCC1806 cells as previously shown 4 ; this enabled direct comparison with results from silencing the target. Silencing of ASCT2 (Fig. 4a) and V-9302 exposure (Fig. 4b) in HCC1806 cells resulted in analogous downstream effects, including markedly decreased phosphorylated (p)-S6 levels and a modest decrease in p-ERK levels. A similar inhibitory profile was observed in V-9302-treated HT29 cells (Supplementary Fig. 8 ). Using an independent biochemical assay for p-ERK activity, we validated that V-9302 exposure resulted in a statistically significant, concentration-dependent decrease in p-ERK that was not observed following CB-839 exposure in HCC1806 or HT29 cells ( Supplementary  Fig. 9 ). In addition, in vitro V-9302 exposure in HCC1806 cells at concentrations that exceeded the IC 50 for glutamine uptake led to increased levels of oxidized glutathione (GSSG) at the expense of reduced glutathione (GSH; Fig. 4c ) and a corresponding increase in intracellular reactive oxygen species (ROS; Fig. 4d ). V-9302 exposure led to elevated GSSG levels and ROS in HT29 cells, which was similar to what occurred in HCC1806 cells, but these features were not observed following CB-839 exposure (Supplementary Fig. 10 ). Autophagy following V-9302 exposure was observed in multiple cell lines, which was not unexpected when considering the relationship between amino acid withdrawal, regulation of mechanistic target of rapamycin (mTOR), and autophagy 18 . Immunofluorescence analysis (Fig. 4e) revealed that V-9302 exposure in HCC1806 cells led to elevated expression of microtubule-associated protein 1 light chain 3B (LC3B), a marker of autophagy 12 . Autophagic flux was elevated with V-9302 exposure in a concentration-dependent manner in the HCC1806 cell line as well as the HT29 cell line ( Supplementary  Fig. 11a,b) . Combining V-9302 with the lysosomal inhibitor Positive values indicate that the alanine substitution interacts less favorably with V-9302 than the native residue. The total interface score is a weighted summation of the hydrogen-bonding scores, repulsion penalties, solvation energies, and electrostatic potential. Glutamine and V-9302 were evaluated in a homology model of LAT1. (e) Ligand interaction diagram of glutamine or V-9302 in LAT1 visualized in the Molecular Operating Environment (MOE) molecular modeling and simulation package. Steric clash with the surrounding residues is indicated in red (only seen with V-9302). (f) Docking scores for glutamine and V-9302 into LAT1; a similar fit was observed for glutamine in LAT1 and ASCT2, although V-9302 only fits the ASCT2 binding pocket. n = 100 top-scoring poses per condition. P values were determined by Student's t-test. For box plots, the center line is plotted at the median; the box spans from the first quartile to the third quartile; and whiskers represent the minimum to maximum.
chloroquine further increased the number of autophagic vesicles in HT29 cells (Supplementary Fig. 11b ). In contrast, CB-839 exposure did not lead to elevated autophagic flux with or without the addition of chloroquine (Supplementary Fig. 11c ). Combined exposure to chloroquine and V-9302 further decreased cell viability in HT29 and HCT-116 cells relative to that following exposure to a single agent or vehicle. In contrast, CB-839 did not decrease cell viability in these cell lines under identical conditions, nor did it exhibit a combinatorial effect with chloroquine ( Supplementary Fig. 12a,b) . In accordance with modulated oxidative stress and increased oxidation of NAD(P)H by glutathione reductase, V-9302 exposure led to a decreased optical oxidation-reduction (redox) ratio in HCC1806 cells (ratio of NAD(P)H to FAD; Fig. 4f ) 21 and decreased the fluorescence lifetimes of both NAD(P)H and FAD (Supplementary Fig. 13 ). The optical redox ratio of a cell is well conserved and has been highly validated with independent measurements, including glycolytic activity and oxygen consumption. The changes in the optical redox ratio following V-9302 exposure, and their magnitude, are consistent with results from prior studies correlating these measures with inhibition of the PI3K-Akt-mTOR pathway in human breast cancer cells 22 . The efficacy of V-9302 was further evaluated in two CRC organoids developed at the Vanderbilt University Medical Center expressing activating mutations in KRAS and BRAF. The viability of both organoid A-007 (harboring BRAF-V600E) and organoid A-008 (harboring KRAS-G12V; p53-R248Q; PTEN-L140Y) was significantly reduced with exposure to V-9302 (Fig. 4g) . In contrast, the same organoids were not significantly affected by CB-839 exposure (Supplementary Fig. 14) .
Evaluation of V-9302 in vivo
We next evaluated the performance of V-9302 in vivo. We first established that steady-state plasma concentrations were achieved at 4 h post-administration with a half-life of approximately 6 h in healthy mice (Supplementary Fig. 15 ). The effects of acute and chronic V-9302 exposure on plasma levels of glucose and glutamine were also evaluated in healthy mice. Following a single acute V-9302 exposure (4 h), plasma glucose levels in V-9302-treated mice were not significantly different from those in vehicle-treated controls, yet plasma glutamine levels were elevated by approximately 50%; this was likely a pharmacodynamic effect ( Supplementary  Fig. 16a,b) . Plasma glucose levels between mice chronically exposed to V-9302 or vehicle over a 21-d regimen were not significantly different, whereas plasma glutamine levels were slightly decreased in the V-9302-exposed mice (Supplementary Fig. 16c,d ). To evaluate the effect of V-9302 on glutamine levels in tumors, we employed noninvasive positron emission tomography (PET) imaging using [4-18 F]fluoroglutamine 5 . Following a single dose of V-9302 (75 mg per kg body weight, 4 h), [ 18 F]-4F-glutamine uptake in tumors in mice bearing HCC-1806 cell-line xenografts (n = 4) was reduced by approximately 50%, reaching levels below background uptake in healthy muscle (Fig. 5a-c) . Unlike what occurred in tumors, [4- 18 F]fluoroglutamine uptake in muscle was unaffected by V-9302 exposure (Fig. 5c) , whereas [4-18 F]fluoroglutamine uptake in liver was modestly elevated (P = 0.05, Student's t-test) following V-9302 treatment. We next carried out chronic-exposure studies in tumor-bearing mice. Athymic nude mice (Hsd:Athymic nude-Foxn1 nu ) bearing HCT-116 (KRAS-G13D) or HT29 (BRAF-V600E) cell line xenografts were treated with 75 mg V-9302 per kg body weight per day for 21 d. Over the treatment course, V-9302 prevented tumor growth as compared to vehicle in both HCT-116 ( Fig. 5d) and HT29 ( Fig. 5f ) xenograft models. Consistent with results from the in vitro mechanistic studies, V-9302 led to significantly decreased expression of p-S6 in tumor tissue in both HCT-116 (Fig. 5e) and HT29 (Fig. 5g) xenografts. In addition to decreased p-S6 IHC staining, V-9302 treatment led to elevated levels of cleaved caspase 3 in both HCT-116 (Fig. 5e) and HT29 (Fig. 5g) xenografts. To evaluate V-9302 in a more clinically relevant model, we conducted a similar chronic-exposure study in mice bearing a patient-derived xenograft (PDX) tumor (A-008: KRAS-G12V; p53-R248Q; PTEN-L140Y). Over the treatment course, V-9302 exposure led to a reduction in tumor volume as compared to vehicle exposure (Fig. 5h,i) the course of the chronic-exposure studies, no substantial weight loss was observed in V-9302-treated cohorts relative to vehicle-treated controls (Supplementary Fig. 19 ). Additionally, liver pathology was similar among mice chronically treated with either V-9302 or vehicle (Supplementary Fig. 20 ).
To globally evaluate the in vivo effects of V-9302 on tumors, we carried out an unbiased metabolomics analysis of HT29 xenografts following 21 consecutive days of V-9302 exposure or vehicle treatment. A total of 782 metabolites of known identity that span 50 distinct metabolic pathways were quantitatively evaluated by liquid chromatography-mass spectrometry (LC-MS, Metabolon; Supplementary Data 1). Notably, V-9302 exposure significantly (P < 0.05, Welch's two-sample t-test) impacted 239 metabolites that spanned seven metabolic categories (Fig. 6a) , each attributable to various aspects of ASCT2 transport and glutamine metabolism. Certain metabolites impacted by V-9302 treatment were directly downstream of ASCT2 transport, such as Nacetylserine, which was reduced in V-9302-treated tumors by greater than fourfold. Evidence of V-9302's impact on ATP included significantly reduced creatine phosphate levels in treated tumors. Levels of GSSG and 4-hydroxynonenal-glutathione were significantly elevated following V-9302 exposure, confirming earlier in vitro studies that identified oxidative stress as a key impact of V-9302 treatment. Other families of metabolites, including various nucleotide sugars, amino sugars, and metabolites within the pentose phosphate pathway 23, 24 , were also elevated; this appeared to indicate a compensatory metabolic shift to glucose metabolism. Several metabolites impacted by V-9302 treatment were related to membrane biosynthesis and integrity. Numerous phospholipids, phosphatidylethanolamines, ceramides, and cholesterol metabolites, which are largely consistent with an autophagic fingerprint [25] [26] [27] [28] [29] , were modulated by V-9302 exposure.
DISCUSSION
The diversity of metabolic pathways that cancer cells rely upon represents a key opportunity for drug development and precision medicine. It is well recognized that energy production in cancer cells is uniquely dependent upon specific nutrients, such as glucose and glutamine. Despite overwhelming evidence illuminating the prominent role of glutamine in cancer cell growth and homeostasis, few efforts have resulted in therapies capable of effectively antagonizing glutaminolysis thus far.
Mitochondrial glutaminase (GLS1), the enzyme responsible for catalyzing the conversion of glutamine to glutamate, represents a potentially promising target. Glutaminase is elevated in many tumors and tends to be associated with high-grade lesions 30 . Studies evaluating genetic silencing of GLS1 activity encouraged the development of GLS1 inhibitors [31] [32] [33] . One compound, CB-839 (Calithera Biosciences), is a selective GLS1 inhibitor now being explored clinically in multiple solid and liquid tumors 10 .
Here we report on V-9302, the first selective and potent small molecule antagonist of a glutamine transporter. We hypothesized that blocking cellular glutamine transport would impart a greater impact on glutamine metabolism in cancer cells than targeting downstream enzyme activity (for example, GLS1), particularly given the extensive biological plasticity leveraged by cancer cells to maintain intracellular glutamate pools. The new inhibitor V-9302 is distinct from investigational therapies targeting glutamine metabolism, as it is designed to abrogate all facets of glutamine signaling and metabolism downstream of ASCT2-mediated import. This differs dramatically from glutaminase inhibitors, which largely overlook the role of glutamine on MAPK signaling 11 , the activity of GLS2 (ref. 34) , and the activity of amino acid transporters that require glutamine antiport for their function (for example, LAT1) 18 . Specifically antagonizing ASCT2, as shown in this study, results in another distinguishing feature of V-9302: the ability to block ASCT2-mediated transport of additional neutral amino acids beyond glutamine (Fig. 6) . Although abrogation of cancer cell glutaminolysis represents a central motivation for the development of V-9302, it cannot be ruled out that the observed efficacy in vivo may be due, in part, to combinatorial blockade of multiple ASCT2 substrates. Although we observed that glutamine withdrawal or combinatorial ASCT2-substrate withdrawal had essentially indistinguishable effects on cell viability in V-9302-sensitive cancer cells, combinatorial depletion of ASCT2 substrates led to enhanced cell death in a portion of the cell lines evaluated. Collectively, these factors may, at least in part, explain the difference in efficacy between V-9302 and CB-839 observed in this study. The compound reported here also exhibits unique qualities that another reported inhibitor of glutamine uptake, GPNA, does not. Previously reported as an ASCT2 inhibitor, GPNA exhibits poor potency and selectivity in human cells 14, 35 .
We identified several molecular determinants associated with response to V-9302; many of these affect facets of cancer cell growth and proliferation, cell death, and oxidative stress (Fig. 6b) . In multiple models, V-9302 exposure resulted in decreased mTOR activity as assessed by p-S6 and p-Akt (Ser473) levels, which is consistent with diminished amino acid transport and metabolism 18 . Indeed, we found that mice treated chronically with V-9302 exhibited decreased plasma glutamine levels, which suggests, in part, diminished exchange via LAT1. In support of this, mTOR activity following V-9302 was decreased in all models evaluated. In spite of this, we observed elevated p-PRAS40 levels in V-9302-treated COLO 205 xenografts, suggesting prosurvival cap-dependent translation 36 . Although Akt is known to be a major regulator of PRAS40 phosphorylation, the data presented here point to Akt-independent PRAS40 regulation, perhaps through proto-oncogene PIM-1 (ref. 37) . Interestingly, the observed increase in p-GSK-3β levels in COLO 205 xenografts following V-9302 treatment could also be explained by PIM-1 activity 38 , suggesting potential synergy between V-9302 and an inhibitor of the PIM-1 kinase. Data stemming from global metabolomic analysis were also consistent with impaired amino acid transport in V-9302-treated tumors, with a considerable impact on metabolites related to the ASCT2 substrates glutamine and serine. Given the anaplerotic nature of glutamine, it was not surprising that metabolites related to ATP production were diminished in V-9302-treated tumors. We consistently observed that V-9302 exposure led to diminished p-ERK levels in tumor cells in vitro and in vivo, which is potentially related to an extra-mitochondrial role for glutamine. Although V-9302 treatment did not fully abolish p-ERK levels, it was intriguing that V-9302-treated COLO 205 xenografts exhibited both decreased p-ERK and decreased BrdU incorporation, suggesting diminished proliferation. Indeed, prior studies have shown that glutamine can activate MAPK signaling independently of EGFR ligand activation 39 , suggesting that glutamine deprivation may exert antiproliferative effects, as shown here.
Elevated autophagy was another notable characteristic of the V-9302-mediated response in vitro and in vivo. Combining V-9302 with an autophagy inhibitor further decreased the viability of V-9302-sensitive cells, as elevated autophagy was likely a prosurvival response to substrate starvation; this potentially illuminates a future therapeutic strategy using combination treatment. In addition to autophagy, substantially elevated apoptosis was frequently observed in V-9302-treated tumors. Given that autophagy in this setting appeared to be protective, it is likely that the cell death response to V-9302 was mediated at least in part by apoptosis.
A third feature of the response to V-9302 was elevated oxidative stress. Frequently derived from glutamine, glutathione is a key modulator of oxidative stress. We observed that V-9302 impacted the redox state of glutathione in multiple models, leading to correspondingly increased levels of ROS. Additional markers elevated in V-9302-treated COLO 205 xenografts attributable to oxidative stress included elevated cleaved PARP, p38, and p53.
In summary, we report the first pharmacological inhibitor, to our knowledge, of the glutamine transporter ASCT2. These results not only illustrate the promising nature of the lead compound V-9302 but also support the concept that antagonizing glutamine metabolism at the transporter level represents a potentially viable approach in precision cancer medicine. Pairing patients harboring glutaminedependent tumors with this new class of inhibitors will require validated biomarkers. As the expression of a transporter alone does not necessarily correlate with its activity, we were not surprised that the response to V-9302 did not correlate with levels of ASCT2 expression in tumors. Furthermore, larger studies are needed to evaluate correlates of V-9302 response and oncogene status. However, we did note that tumor cells sensitive to V-9302 were also sensitive to glutamine withdrawal as well as ASCT2 substrate withdrawal, suggesting that response to V-9302 is likely a function of transporter activity and a tumor's reliance upon that. Furthermore, considering that combining V-9302 with an inhibitor of autophagy resulted in a greater impact on cell viability, it cannot be ruled out that sensitivity to V-9302 may be predicated by a cancer cell's ability to use autophagy as a means to rescue the ASCT2-substrate-deprived phenotype. Importantly, the activity of ASCT2 can be quantitatively assessed using noninvasive PET imaging of glutamine uptake, which may represent a translational biomarker reflective of tumors likely to respond to V-9302 and similar agents.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
ONLINE METHODS
General methods and reagents and supplies. All reagents and supplies were obtained from commercial suppliers and in some cases were further purified on an as-needed basis. Analytical thin-layer chromatography (TLC) was performed on silica gel plates from Sorbent Technologies with direct visualization via ultraviolet (UV) light and/or the use of ninhydrin or potassium permanganate staining. Chromatographic purification of intermediates was performed using silica or RediSep Rf C18 flash columns on a CombiFlash Rf automated chromatography system. All 1 H and 13 C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AV400 (400 MHz and 100 MHz, respectively). All 1 H and 13 C chemical shifts are reported in parts per million (p.p.m.) relative to residual solvent peaks. CB-839 was obtained from Calithera Biosciences. Immortalized cell lines were purchased from commercial vendors (ATCC) and were authenticated using a commercial vendor (Genetica). Mice were purchased from Enivgo and used in accordance with Institutional and Federal guidelines. All animal procedures were approved by the Vanderbilt University Institutional Animal Care and Use Committee (IACUC). Human CRC organoids were obtained from subjects enrolled in a clinical trial at Vanderbilt University Medical Center in accordance with an Institutional Review Board (IRB)-approved protocol. For all statistical comparisons, the variance between groups being compared was similar.
Synthesis of V-9302. V-9302 was prepared as previously described 13 . For this study, V-9302 was purified by reverse phase (C18) column chromatography (10-90% acetonitrile in water gradient over 60 min), giving a final yield of up to 72% over two steps. 1 General procedure for 3 H-labeled amino acid uptake assays. Live-cell amino acid uptake assays using HEK-293 cells were carried out in 96-well plates (CulturPlate-96, Perkin Elmer). 96-well plates were coated with poly-D-lysine before the assay. Cells were plated at a density of 35,000 cells per well 24 h before carrying out the assay. Each set of conditions was replicated at least three times, technically and biologically (three experiments performed in triplicate). Cells were washed three times with 100 µl of assay buffer (containing 137 mM NaCl, 5.1 mM KCl, 0.77 mM KH 2 PO 4 , 0.71 mM MgSO 4 ·7H 2 O, 1.1 mM CaCl 2 , 10 mM D-glucose, and 10 mM HEPES) to remove cell media. [ 3 H]amino acid (500 nM) in the same buffer was added concomitantly with V-9302 and allowed to incubate for 15 min at 37 °C. For ASCT2-mediated [ 3 H]glutamine uptake assays, 5 mM of the system L inhibitor 2-amino-2-norbornanecarboxylic acid (BCH) was added and the assay buffer was adjusted to pH 6.0. For selectivity studies, no BCH was added and the assay was conducted at pH 7.4. Following the incubation period, the [ 3 H]glutamine and inhibitor were removed, and cells were washed three times with assay buffer. The cells were then lysed through the addition of 50 µl 1 M NaOH. For reading, 150 µl of scintillation fluid (Microscint 40, Perkin Elmer) was added, and the plates were counted on a scintillation counter (Topcount, Perkin Elmer). IC 50 values were calculated using GraphPad Prism version 6 for Mac OS X (GraphPad Software, San Diego, CA USA; http://www.graphpad.com/). Error is reported as s.d.
Procedure for in silico docking studies of V-9302.
A model of an inhibitorbound conformation of hASCT2 was used as a target for ligand docking of V-9302. 2D structures for all ligands were generated in ChemDraw, imported into Tripos Sybyl for conversion into 3D structures using CONCORD, and docked using RosettaLigand 40 . Figures for docked complexes were generated and raytraced using PyMOL (The PyMOL Molecular Graphics System, Version 1.5.0.4, Schrodinger, LLC). In addition, fragment constraints were used to encourage placement of the amino acid analog main-chain atoms in a location analogous to the positions that were experimentally determined for (2S, 3S)-3-[3- [4- (trifluoromethyl)benzoylamino]-benzyloxy]aspartate (TFB-TBOA) in its cocrystal structure within the homologous human excitatory amino acid transporter 1 (hEAAT1; Protein Data Bank (PDB) ID: 5MJU) protein 16 . Seeding the docking calculations in this way yielded better-scoring docking poses using the empirically derived scoring function, suggesting that this feature of the binding interaction may be conserved between these two systems.
For comparative studies of ASCT2 and LAT1, predictive structures used for docking were generated using homology modeling. To determine suitable template structures, the primary sequence of ASCT2 was extracted from gene SLC1A5 (UniProt Knowledgebase (UniProtKB) ID: Q15758). Using the PDB Search tool within MOE (version 2014.09, Chemical Computing Group), ASCT2 alignments were generated with the crystal structure of hEAAT1. The primary sequence of LAT1 used to determine predictive structures was extracted from gene SLC7A5 (UniProtKB ID: Q01650). LAT1 homology model structures were generated from crystal structures of the Arg + -bound conformation of Escherichia coli AdiC and the ApcT transporter derived from Methanocaldococcus jannaschii (PDB IDs: 3L1L and 3GIA, respectively). MOE's homology model application generated initial structures with a well-conserved binding pocket using the templates and respective sequence alignments. All resulting ASCT2 and LAT1 structures underwent energy minimization using Amber12 force field potentials and protonation. In order to mimic the lipid bilayer environments of ASCT2 and LAT1, homology models were embedded and relaxed into the membrane using the RosettaMP framework. Upon further refinement, top scoring models of both ASCT2 and LAT1 were used for docking simulations of V-9302 and additional ligands according to the RosettaLigand protocol. Ligand rotational conformer libraries were generated using energy minimization in MMFF94x force field potentials and then screened using the MOE conformer search tool. The binding site was identified using prior knowledge of homology binding sites and Surflex-Dock results. Each simulation consisted of 500 iterations while scoring the protein-ligand interface energies. Final models were sorted based on interface_delta_X scores, and evidence regarding steric hindrance penalties was extracted on the basis of if_X_fa_rep energies.
In silico alanine scan. Docking studies were performed to place V-9302 into the amino acid-binding site of an ASCT2 homology model. The highest scoring poses were found when the constraints were enabled to favor poses that anchored the amino acid moiety of the ligands to a similar binding orientation as TFB-TBOA in the structure of the homologous protein hEAAT1. In silico mutagenesis experiments were conducted by individually changing side chains to alanine without otherwise changing the conformation of the protein or ligand in Rosetta. RosettaLigand was then used to rescore the same V-9302 docking pose with each of these Ala mutants. The docking score for each mutant was then compared with the score for the WT model to assess the WT side chain contribution to the overall score in this binding pose.
Generation of HEK-293 cells with tetracycline-inducible ASCT2 expression.
T-REx-293 cells (Invitrogen R71007) were transfected with the plasmid pCDNA5-TO-h-SLC1A5 (Invitrogen V1033-20) according to the manufacturer's protocol. The cloning sites consisted of Not1 and XbaI sites; insert OriGene SC116600. Stably transfected clones were selected via hygromycin (150 µg/ml).
Drug affinity responsive target stability assay. DARTS was carried out as previously described 15 using T-REx-293 cells with tetracycline-inducible expression of ASCT2 or lysate from 115 mg of homogenized mouse brain for ASCT1. Lysates were exposed to V-9302 at varying concentrations for 35-45 min at room temperature with shaking. Lysates were then incubated at room temperature with the protease Thermolysin (1:100 and 1:200 total enzyme to total substrate) for 30 min. ASCT2 was measured by immunoblotting (ASCT2 antibody: Millipore ABN73; ASCT1 antibody: Cell Signaling 8442).
shRNA. HCC1806 cells were transfected with a lentiviral vector (pLKO.1) containing control shRNA (Sigma SHC002V) or shRNA against ASCT2 (Sigma SHCLNV-NM_005628): 5′-CCGGCTGGATTATGAGGAATGGATACTCGA GTATCCATTCCTCATAATCCAGTTTTTG-3′. ASCT2 expression was measured by immunoblotting (ASCT2 antibody: Millipore ABN73) at 72 h post transduction and after puromycin selection.
Cell viability screens. Viability was evaluated using commercially available chemiluminescent reagents (CellTiter-Glo, Promega Corp. G7572; MultiTox Glo, Promega Corp. G9270) in 96-well-plate format according to the manufacturer's protocols. Cells were exposed to vehicle, V-9302, CB-839, V-9302 + chloroquine (CLQ), or CB-839 + CLQ and incubated for a period of 48 h. Subsequently, CellTiter-Glo reagent was added, and the plates were read using a plate reader (BioTek Synergy 4) with standard settings. Each set of conditions was replicated at least three times, technically and biologically. Error is reported as s.d. The sulforhodamine B assay was run analogously to the above assays as previously described 19 .
Measurement of glutathione and reactive oxygen species. Glutathione levels were measured using a commercially available kit (Cayman Chemical 703002) according to the manufacturer's protocol. ROS were concurrently measured in cells using CM-H2DCFDA (Life Technologies C6827) coupled with flow cytometry in accordance with the manufacturer's protocol. The assay was replicated at least three times, technically and biologically. Significance was calculated using a t-test in GraphPad Prism. Error is reported as s.d.
Measurement of p-ERK.
Detection of activated ERK in cell lysates was enabled by the AlphaScreen SureFire ERK assay (Perkin Elmer) performed according to the manufacturer's protocol. Cells were plated in 96-well plates for 24 h before the assay. Cells were treated with either vehicle or the indicated concentrations of V-9302 or CB-839 for 48 h (Supplementary Fig. 9 ).
Measurement of autophagic flux. Autophagic flux was measure using the CYTO-ID autophagy detection kit (Enzo Life Sciences ENZ-51031). HCC1806 and HT29 cells were seeded in 96-well plates the day before the experiment. After overnight incubation, cells were treated with V-9302, CB-839, and 500 nM rapamycin as a positive control or the combinations thereof with 10 µM CLQ for 18 h. Following treatment, cells were gently washed with assay buffer followed by addition of the dual-color detection solution and incubation at 37 °C for 30 min. The plate was analyzed on a fluorescence microplane reader (BioTek Synergy 4).
Immunoassays. For immunoreactivity studies, tissue samples were diluted to 100 mg/ml in lysis buffer (Cell Signaling Technology 7018s) and subsequently homogenized, sonicated, and spun at 3,500 r.p.m. for 1 min. Lysate samples were then screened against an array of target-specific capture antibodies using PathScan Intracellular Signaling Array Kits (Cell Signaling Technology 7323) in accordance with the manufacturer's instructions and were developed using HyBlot CL autoradiography film (Denville Scientific, Inc., e3012). Processed films were digitized using an Epson Perfection V600 Photo scanner, and the relative pixel intensities for each blot were quantified using the image processing software ImageJ. Complementary western blot studies were performed through loading 20-40 µg of protein into 7.5-12% SDS-PAGE gels, which were transferred to PVDF membranes (Perkin Elmer) and resolved using electrophoresis. Membranes were blocked overnight at 4 °C in Tris-buffered saline with 0.1% Tween-20 (TBST) containing 5% nonfat dry milk powder and were subsequently incubated with antibodies against p-ERK1 (Thr202) and p-ERK2 (Tyr204) (Cell Signaling 4370), p-S6 (Cell Signaling 4858), LC3B (anti-LC3B, Cell Signaling 2775), or β-tubulin (Novus Biologicals NB600-936). Membrane chemiluminescence was visualized on a Xenogen IVIS 200 system.
Immunofluorescence. HCC1806 cells were treated with V-9302 (25 µM aqueous, 1% DMSO) for 48 h. Following treatment, cells were fixed with 70% methanol for 5-10 min. LC3B was visualized with 1:100 primary antibody (anti-LC3B, Cell Signaling 2775) at 37 °C for 45 min followed by application of 1:600 secondary antibody (Rhodamine Red, Invitrogen R6394) at 37 °C for 30 min and DAPI for 4 min. Images were acquired with a fluorescence microscope and were visualized at 40× magnification.
In vivo BrdU incorporation assay. Four hours after the final treatment, mice were injected with BrdU labeling reagent (Zymed Laboratories, South San Francisco, CA). Six hours after injection, the mice were killed. Mouse tumors were harvested, fixed in paraffin, and sectioned. Slides were stained with antiBrdU primary antibody (mouse IgG; Life Technologies 03-3900) followed by Rhodamine Red-labeled goat anti-mouse secondary antibody (ThermoFisher R-6393, Invitrogen Molecular Probes, Carlsbad, CA). Sections were counterstained with the nucleic acid dye DAPI. Photographs were taken, scanned into Photoshop software, and quantified. The mean and standard error of BrdU-incorporating cells were determined (n = 3). To quantify endothelial cell proliferation in vivo, high-power photographs were taken. The endothelial cells surrounding blood vessels were confirmed by two separate observers and quantified for each treatment condition as stated above (n = 6).
Immunohistochemistry. For immunohistochemistry, mice were euthanized, and tumor tissue samples were collected within 4 h of the final V-9302 dose, fixed in 10% formalin for 24 h, and then stored in 70% ethanol in PBS. Tissues were sectioned (5-µm thickness) and stained for p-S6 (Cell Signaling 4858) and caspase 3 (Cell Signaling 9661). Tissue slides were imaged at 20× magnification.
Fluorescence redox ratio imaging. HCC 1806 cells were plated on 35-mm glass-bottom petri dishes for imaging (MatTek Corp). Fluorescence intensity and lifetime images were acquired using a custom-built multiphoton fluorescence lifetime system (Bruker), with a 40× oil-immersion objective (1.3 NA) and an inverted microscope (TiE, Nikon). A titanium:sapphire laser (Chameleon Ultra II, Coherent) was tuned to 750 nm for two-photon excitation of NAD(P)H and tuned to 890 nm for two-photon excitation of FAD. A 440/80-nm bandpass filter was used to collect NAD(P)H fluorescence emission, and a 550/100-nm bandpass filter was used to collect FAD emission. A pixel dwell time of 4.8 µs was used to collect images that were 256 pixels × 256 pixels, with a total integration time of 60 s. A GaAsP photomultiplier (PMT; H7422P-40, Hamamatsu) detected emitted photons. The field of view acquired was 270 µm × 270 µm, and six fields of view were acquired per treatment group. Time-correlated single-photon counting electronics (SPC-150, Becker & Hickl) were used to acquire fluorescence decay curves. The second harmonic-generated signal from urea crystals at 900-nm excitation was used to measure the instrument response function, which was found to have a full width at a half maximum of 220 ps. Fluorescence lifetime validation was performed through imaging a fluorescent bead (Polysciences, Inc.) and confirming that the measured lifetime (2.1 ns) agreed with previously published values 22 . The assay was replicated at least three times with technical and biological replicates.
A histogram of photon counts per temporal bin (decay curve) was constructed for each pixel in the image and then deconvolved with the instrument response function. Decay curves were then fit to a two-component exponential decay to account for the distinct free and protein-bound lifetimes of NAD(P)H and FAD using SPCImage software (Becker & Hickl). The decay fit is given by equation (1), where I(t) represents the fluorescence intensity measured at time t after the laser pulse; α 1 and α 2 represent the fractional contributions of the short and long lifetime components to the overall intensity, respectively; T 1 and T 2 represent the fluorescence lifetimes of the short and long lifetime components, respectively; and C represents a constant level of background light.
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The mean lifetime (T m ) of NAD(P)H or FAD represents the weighted average of the short and long lifetime components (Equation (2)).
An automated cell segmentation routine was written using CellProfiler to identify individual cell cytoplasms and extract average fluorescence intensity and fluorescence lifetime values for each cell in the field of view. Intensity values for each pixel were calculated through integrating the decay curve for each pixel. Optical redox ratio values were calculated for each cell by dividing the average intensity of NAD(P)H by the average intensity of FAD. Optical redox ratio values were normalized to vehicle. For each imaging endpoint, values for all cells imaged in each treatment group were averaged together to generate mean and standard error values. An unpaired t-test with Welch's correction was performed for all comparisons of imaging values.
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Organoid culture and viability assay. Human CRC-derived organoids were prepared following a previously reported method with modification 41 . Briefly, specimens from freshly resected tumors were minced and digested with 2 mg/ml type 2 collagenase (Worthington, NJ, USA). Samples were passed through 40-µm filters (Greiner Bio One, NC, USA), and epithelial cells trapped on the filters were embed in Matrigel (Corning, MA, USA) and cultured with advanced DMEM/F-12 supplemented with N2 and B27 supplements (Thermo Fisher, MA, USA), 50 ng/ml recombinant human epidermal growth factor (rhEGF; R&D Systems, MN, USA), and 1% Antibiotic-Antimycotic (Corning). For the viability assay, organoids were dissociated by TrypLE express (Thermo Fisher) and suspended in Matrigel. 5 µl of cell suspension in Matrigel drops was placed into untreated 96-well plates (Corning) and overlaid with experimental medium, which consisted of V-9302, CB-839, or vehicle at the indicated concentration ( Fig. 4g and  Supplementary Fig. 14) in advanced DMEM/F12 supplemented with N2 and B27 supplements, 1% Antibiotic-Antimycotic, and 4 mM l-glutamine (GE Healthcare, OH, USA). After 4 d of culture, images of the organoids in Matrigel were captured and the number of viable cells was quantified with CellTiter Aqueous One Cell Proliferation Assay kit (Promega, WI, USA) and a Synergy 4 plate reader (BioTek, VT, USA). The assay was replicated at least three times with technical and biological replicates. Significance was calculated using a t-test in GraphPad Prism. Error is reported as s.d.
V-9302 plasma stability assay. Whole-blood samples (n = 5 mice) were assayed for V-9302 levels with respect to time by Sano Informed Prescribing, Inc. (Franklin, TN) . Liquid chromatography-tandem mass spectroscopy (LC-MS/MS) analyses were performed via reverse-phase chromatography using a Shimadzu Nexera X2 UPLC (Columbia, MD) coupled with a QTrap 5500 (Sciex, Framinghman, MA, USA). A standard curve and quality-control samples were made by spiking V-9302 into fresh whole blood and then applying this to 10 µl Mitra Microsamplers (Neoteryx, LLC, Torrance, CA). Blank samples were made using fresh whole blood applied to Mitra Microsamplers and were allowed to dry for at least 24 h. All data were collected using Sciex Analyst 1.6.2 software and analyzed with MultiQuant 3.0 software. Error is reported as s.d.
Plasma metabolite analysis.
To quantify plasma glutamine and glucose, whole blood was collected from healthy mice (n = 10) chronically exposed to V-9302 (75 mg per kg body weight, daily) or vehicle. Mice were euthanized 4 h after the final treatment. Following centrifugation, plasma was collected and 50 µl was added to a 96-well plate in triplicate. Plasma samples were diluted with 50 µl of assay buffer (YSI 2357), and glucose and glutamine were quantified directly using a YSI 2950D Biochemistry Analyzer (YSI, Inc.). Significance was calculated using a t-test in GraphPad Prism. Error is reported as s.d.
CD8 + cell studies. CD8 + cells were isolated from spleens of 8-to 12-weekold C57BL6 mice on standard chow from Jackson Labs maintained under Vanderbilt University Institutional Animal Care and Use Committee (IACUC)-approved protocols. CD8 + cells were stained using the proliferative dye Cell Trace Violet (LifeTech) before stimulation per the manufacturer's protocol. Cells were stimulated on 5 µg/ml anti-CD3-and anti-CD28-coated plates in medium containing IL-2 ('activated' , 10 ng/ml) or on tissue-culturetreated plates in medium containing IL-7 ('naive' , 1 ng/ml) for up to 7 d. Cells were removed daily, and their viability, cell counts, proliferation, and surface markers of activation were described. The cell-surface markers used were CD62L-FITC and APC, CD44-PE/Cy5, and CD25-PE. All data were acquired in triplicate on a MacsQuant Analyzer (Miltenyi Biotec) and analyzed using FlowJo version 10 (TreeStar software). [4-18 F] fluoroglutamine and the requisite tosylate precursor were produced as previously reported 5 .
Synthesis of [4-18 F]fluoroglutamine.
Positron emission tomography imaging and analysis. Mouse handling methods for PET imaging studies were as previously reported 5, 42 . Prior to imaging, mice were allowed to acclimate to the facility environment for at least 1 h in a warmed chamber at 31.5 °C. Mice were administered 10.4-11.8 MBq Committee. Written informed consent was obtained from all patients prior to tissue collection. The tumor tissue was genotyped within the VANTAGE core facility. The xenograft was generated as previously described 41 . Briefly, tumor tissues were sectioned into approximately 125-mm 3 pieces and then implanted subcutaneously without further manipulation. PDX tumors were propagated to the F 3 generation for V-9302 treatment studies. For treatment, V-9302 was reconstituted in a vehicle of PBS supplemented with 2% DMSO and administered intraperitoneally. Tumor volumes were measured manually using calipers every third day and were quantified using the formula V = W × L × (H/2).
Metabolomics. HT-29 (n = 10) tumor samples were harvested and snap frozen within 4 h of the final dose of V-9302 or vehicle. Metabolomic data acquisition was outsourced to Metabolon, Inc. Samples were prepared using the automated MicroLab STAR system from Hamilton Company. To remove protein, dissociate small molecules bound to protein or trapped in the precipitated protein matrix, and recover chemically diverse metabolites, proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000), which was followed by centrifugation. The resulting extract was divided into five fractions: two for analysis using two separate reverse-phase ultra-performance liquid chromatography-tandem mass spectrometry (RP/UPLC-MS/MS) methods with positive-ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with negative-ion mode ESI, one for analysis by hydrophilic interaction chromatography (HILIC)/UPLC-MS/MS with negative-ion mode ESI, and one sample that was reserved for backup. Samples were placed briefly on a TurboVap (Zymark) to remove the organic solvent. All procedures used a Waters ACQUITY UPLC and a Thermo Scientific Q-Exactive high-resolution/ accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and an Orbitrap mass analyzer operated at 35,000 mass resolution. The sample extract was dried and then reconstituted in solvents compatible with each of the four methods. Each reconstituted solvent contained a series of standards at fixed concentrations to ensure injection and chromatographic consistency. One aliquot was analyzed using acidic positive-ion conditions that were chromatographically optimized for more hydrophilic compounds. In this method, the extract was gradient eluted from a C18 column (Waters UPLC BEH C18, 2.1 mm × 100 mm, 1.7 µm) containing 0.05% perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA) using water and methanol. Another aliquot was also analyzed using acidic positive-ion conditions; however, it was chromatographically optimized for more hydrophobic compounds. In this method, the extract was gradient eluted from the same aforementioned C18 column using methanol, acetonitrile, water, 0.05% PFPA, and 0.01% FA and was operated at an overall higher organic content. Another aliquot was analyzed using basic negative-ion-optimized conditions using a separate dedicated C18 column. The basic extracts were gradient eluted from the column using methanol and water with 6.5 mM ammonium bicarbonate at pH 8. The fourth aliquot was analyzed via negative ionization following elution from a HILIC column (Waters UPLC BEH Amide, 2.1 mm × 150 mm, 1.7 µm) using a gradient consisting of water and acetonitrile with 10 mM ammonium formate, pH 10.8. Raw data were extracted, peak-identified, and quality-control processed using Metabolon's hardware and software. Compounds were identified through comparison with library entries of purified standards or recurrent unknown entities. Metabolon maintains a library based on authenticated standards that contains the retention time/index (RI), mass to charge ratio (m/z), and chromatographic data (including MS/MS spectral data) for all molecules present in the library. Furthermore, biochemical identifications were based on three criteria: retention index within a narrow RI window of the proposed identification, accurate mass match to that in the library ± 10 p.p.m., and the MS/MS forward and reverse scores matched between the experimental data and authentic standards. The MS/MS scores are based on a comparison of the ions present in the experimental spectrum to the ions present in the library spectrum. Peaks were quantified using area under the curve. For studies spanning multiple days, a data normalization step was performed to correct for variation resulting from instrument interday tuning differences. For many studies, two types of statistical analysis were performed: significance tests and classification analysis. Standard statistical analyses were performed in ArrayStudio on log-transformed data. For those analyses that were not standard in ArrayStudio, R (http://cran.r-project.org/) or JMP was used.
Statistics and reproducibility. Sample sizes and statistical tests for each experiment are denoted in the figure legends or the respective methods section. All analyses and graphs were generated with GraphPad Prism 6. P < 0.05 was considered significant; exact P values can be found in the figures. 
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